Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

After the recent approval of its first all-oral hepatitis C regimen, the China FDA is striving to approve within a year more direct-acting antiviral (DAA) therapies to treat all genotypes of the disease, setting the stage for both multinational and domestic pharma firms to compete in the world’s largest HCV drug market.